In the overall cohort, univariate followed by multivariable logistic regression estimated the risk of sites of recurrence (first and first plus subsequent sites of recurrence).
Combining first and subsequent sites of recurrence, 40% of HR-negative patients and 33% of HR-positive patients had brain involvement.
Combining first and subsequent sites of recurrence, brain involvement was present in 40% of patients with documented recurrence of HR-/HER2+ breast cancer and in 33% of patients with documented recurrence of HR+/HER2+ tumors.
Subsequent sites of interaction are topics for future research.
A retrospective chart review was conducted to identify clinicopathologic variables, treatment, and subsequent sites of metastasis.
A lower risk of recurrence in bone persisted after adjusting for age, stage and adjuvant trastuzumab therapy (OR = 0.53, 95% CI: 0.34 to 0.83, P = 0.005) and when first and subsequent sites of recurrence were both considered (multivariable OR = 0.55, 95% CI: 0.37 to 0.80, P = 0.002).
As such, combining first and subsequent sites of recurrence, patients with HR-negative tumors were slightly more likely to experience lung involvement (OR = 1.48, 95% CI: 1.00 to 2.18, P = 0.05) and less likely to recur in bone (OR = 0.54, 95% CI: 0.37 to 0.78, p= 0.001).
The guidelines and training curriculum became a key element of the subsequent site registration and quality assurance systems.
Under a purely random distribution, the distance from one selected site to the next would be expected to follow a geometric distribution because the probability of each subsequent site being under positive selection will be equal.
